Piper Jaffray Cos. upgraded shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) from a neutral rating to an overweight rating in a research note issued to investors on Monday morning.

Other equities analysts have also issued research reports about the company. Oppenheimer Holdings Inc. reiterated a buy rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a research note on Sunday, July 17th. Wedbush reiterated a neutral rating and issued a $14.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, May 25th. SunTrust Banks Inc. reiterated a reduce rating on shares of Sarepta Therapeutics in a research note on Friday, May 27th. William Blair upgraded Sarepta Therapeutics from a market perform rating to an outperform rating and set a $88.00 price target on the stock in a research note on Monday. Finally, Janney Montgomery Scott reiterated a hold rating on shares of Sarepta Therapeutics in a research note on Tuesday, June 7th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $51.01.

Sarepta Therapeutics (NASDAQ:SRPT) opened at 56.22 on Monday. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $58.87. The firm’s market cap is $2.69 billion. The firm has a 50-day moving average price of $29.05 and a 200 day moving average price of $21.62.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the company posted ($0.87) earnings per share. Equities analysts predict that Sarepta Therapeutics will post ($4.17) earnings per share for the current year.

In other news, VP Jayant Aphale sold 35,000 shares of the business’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the transaction, the vice president now directly owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares in the company, valued at $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. purchased a new position in Sarepta Therapeutics during the second quarter worth $651,000. Eagle Asset Management Inc. purchased a new position in Sarepta Therapeutics during the second quarter worth $6,756,000. Amici Capital LLC purchased a new position in Sarepta Therapeutics during the first quarter worth $488,000. LGL Partners LLC increased its position in Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock worth $485,000 after buying an additional 1,000 shares during the period. Finally, A.R.T. Advisors LLC purchased a new position in Sarepta Therapeutics during the first quarter worth $7,461,000. 72.09% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.